Pattern of statin exposures reported to Texas poison centers, 1998-2004

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 70, Issue 17, 2007, Pages 1424-1432

  Forrester, Mathias B ^a  

^a TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGITATION; ARTICLE; BLURRED VISION; CARDIOVASCULAR EFFECT; CHILD; COMPARATIVE STUDY; DIARRHEA; DILUTION; DIZZINESS; DROWSINESS; EDEMA; ERYTHEMA; EXPOSURE; EYE IRRITATION; FEMALE; GENDER; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; NAUSEA; OUTCOME ASSESSMENT; PAIN; PARALYSIS; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; THROAT IRRITATION; TIME SERIES ANALYSIS; TREMOR; URTICARIA; VOMITING;

ADOLESCENT; ADULT; AGE FACTORS; ANIMALS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; POISON CONTROL CENTERS; RETROSPECTIVE STUDIES; TEXAS;

EID: 34547800264     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390701382803     Document Type: Article

References (15)

1. Blankenhorn, K., and Lipson, D. 2002. Business watch: 2001 In review: Despite economic challenges, pharmaceutical industry still maintains steady growth. Med. Mark. Med. 37:46-62.
2. Brousseau, M. E. 2003. Statins, super-statins and cholesterol absorption inhibitors. IDrugs. 6:458-463.
3. Carroll, M. D., Lacher, D. A., Sorlie, P. D., Cleeman, J. I., Gordon, D. J., Wolz, M., Grundy, S. M., and Johnson, C. L. 2005. Trends in serum lipids and lipoproteins of adults, 1960-2002. J. Am. Med. Assoc. 294:1773-1781.
4. Cherry, D. K., Burt, C. W., and Woodwell, D. A. 2003. National Ambulatory Medical Care Survey: 2001 Summary. Adv. Data 337:1-44.
5. Hsu, I., Spinler, S. A., and Johnson, N. E. 1995. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann. Pharmacother. 29:743-759.
6. Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., Blasetto, J. W., and STELLAR Study Group. 2003. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92:152-160.
7. Lennernas, H., and Fager, G. 1997. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32:403-425.
8. Ma, J., Sehgal, N. L., Ayanian, J. Z., and Stafford, R. S. 2005. National trends in statin use by coronary heart disease risk category. PLoS. Med. 2:e123.
9. Manoguerra, A. S., Erdman, A. R., Booze, L. L., Christianson, G., Wax, P. M., Scharman, E. J., Woolf, A. D., Chyka, P. A., Keyes, D. C., Olson, K. R., Caravati, E. M., and Troutman, W. G. 2005. Iron ingestion: An evidence-based consensus guideline for out-of-hospital management. Clin. Toxicol. (Phil.a. 43:553-570.
10. McKenney, J. M. 2005. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: Benefits versus risks. Am. J. Cardiol. 96:60E-66E.
11. McKenney, J. M., Jones, P. H., Adamczyk, M. A., Cain, V. A., Bryzinski, B. S., Blasetto, J. W., and STELLAR Study Group. 2003. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: Results from the STELLAR trial. Curr. Med. Res. Opin. 19:689-698.
12. Schiff, G. D., Keehr, L. M., Sai, T. T., and Bult, J. 2002. High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic. Pharmacoepidemiol. Drug Safety 11:643-645.
13. SoRelle, R. 2001. Baycol withdrawn from market. Circulation 104:E9015-E9016.
14. Wax, P. M., Erdman, A. R., Chyka, P. A., Keyes, D. C., Caravati, E. M., Booze, L., Christianson, G., Woolf, A., Olson, K. R., Manoguerra, A. S., Scharman, E. J., and Troutman, W. G. 2005. Beta-blocker ingestion: An evidence-based consensus guideline for out-of-hospital management. Clin. Toxicol. (Phila.) 43:131-146.
15. Woodwell, D. A., and Cherry, D. K. 2004. National Ambulatory Medical Care Survey: 2002 Summary. Adv. Data 346:1-44.